The blood-based RBM dose was based on blood samples collected 2 min, 30 min, 1 h, 2 h, 4 h, 24 h, and 72 h after peptide injection and on the total body activity (retrieved from the whole-body planar images).
But in the SPRINT study, patients' blood pressure was measured after five minutes of quiet rest, and medication dose was based on the mean of three readings.
The CLA dose was based on published responses of dairy cows extrapolated to ewes on a metabolic body weight basis.
Selection of dose was based on previous studies [38, 39].
Kairomone dose was based on the amount of EtOAc.
The assigned phenylephrine dose was based on the response of the preceding subject.
cWhether the dose was based on a kg BW is not evident from the description of the study.
The norepinephrine-equivalent dose was based on prior studies: 1 µg epinephrine equivalent to 1 µg norepinephrine [15].
The TNT dose was based on the publication of Reddy at al., [13].
This dose was based on the quantity of DAPT reported to effectively lower Aβ levels in mice, while allowing daily administration for up to two weeks without mortality or significant morbidity [16], [35], [36].
For pyronaridine-artesunate, drug dose was based on body weight: 20 25 kg, 1 tablet; 26 44 kg, 2 tablets; 45 64 kg, 3 tablets; and 65 90 kg, 4 tablets, i.e. a pyronaridine-artesunate target dose of between 7.2∶2.4 mg/kg and 13.8∶4.6 mg/kg.
